Results 161 to 170 of about 8,219 (198)

Refractory Adult-Onset Localized Cutaneous Langerhans Cell Histiocytosis Successfully Treated with Surgical Intervention: Case Report. [PDF]

Clin Cosmet Investig Dermatol
Tan Y, Zheng J, Yao Y, Xu B, Song H, Wang Y, Bu W, Wang Z.   +7 more
europepmc   +1 more source

Real-World Evidence of Upadacitinib Effectiveness in Moderate to Severe Atopic Dermatitis Patients in Saudi Arabia: A Retrospective Chart Review. [PDF]

Dermatol Res Pract
Saaty SEL, Alshehri HS, Alsharif O, Alali A, Fatani MI, Alajlan A, Hammad S, Elnahal I, Hamad T, Anwar A, Ahmed K.   +10 more
europepmc   +1 more source

Comments on "Prevalence, patient characteristics and outcomes of high-dose upadacitinib in inflammatory bowel disease". [PDF]

Ther Adv Gastroenterol
Altaf A, Memon F, Kumar L.
europepmc   +1 more source

JAK1-preferential inhibition in refractory inflammatory bowel disease: reframing upadacitinib as a strategy for rapid immune recalibration. [PDF]

Front Immunol
Liu X, Wang Y.
europepmc   +1 more source

Eczema Molluscatum in a Patient With Atopic Dermatitis on Upadacitinib and Methotrexate. [PDF]

Cureus
Wiesenhofer H, Waldal G, Patel P, Buttars B, Hamann CR.   +4 more
europepmc   +1 more source

Real-World Effectiveness, Safety, and 36-Month Persistence of Upadacitinib in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: The 3-6 Month Critical Window and the Role of Early Itch Response and Psychotropic Medication Use. [PDF]

J Clin Med
Wang Y, Chen X, Wang Y, Zhu J, Zhang B, Kong D, Tian Y, Yu T, Yu H, Zhu K, Cheng H.   +10 more
europepmc   +1 more source

Marked improvement of isolated acrodermatitis continua of hallopeau with upadacitinib: a case report and literature review. [PDF]

Front Med (Lausanne)
Li M, Zhang GX, Wu YL, Huang HY.
europepmc   +1 more source

Efficacy and safety of upadacitinib in treating immune drift: a single-center, prospective study in China. [PDF]

Front Immunol
Xiang W, Lu J, Zhang S, Zheng W, Li Q.
europepmc   +1 more source

Tacrolimus Bridging and Combination Therapy Following Infliximab and JAK Inhibitor Failure in Ulcerative Colitis: A Case Series. [PDF]

JGH Open
Vootukuru N, Hilley P, Wong D, Srinivasan A, De Cruz P, Choy M.   +5 more
europepmc   +1 more source

Case Report: Glucocorticoids with Early Aggressive Rituximab and Upadacitinib regimen in the treatment of three patients with anti-MDA5 dermatomyositis-associated interstitial lung disease. [PDF]

Front Med (Lausanne)
Wong EKM, Tam LHP, So J, Lam TTO, Choi MY, Tam LS, So H.   +6 more
europepmc   +1 more source